Patents by Inventor Meenu Kesarwani

Meenu Kesarwani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPY FOR KINASE-DEPENDENT MALIGNANCIES
    Publication number: 20200129456
    Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.
    Type: Application
    Filed: June 28, 2019
    Publication date: April 30, 2020
    Inventors: Mohammad AZAM, Meenu KESARWANI
  • Therapy for kinase-dependent malignancies
    Patent number: 10342767
    Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: July 9, 2019
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Mohammad Azam, Meenu Kesarwani
  • THERAPY FOR KINASE-DEPENDENT MALIGNANCIES
    Publication number: 20180360777
    Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 20, 2018
    Inventors: Mohammad AZAM, Meenu KESARWANI
  • THERAPY FOR LEUKEMIA
    Publication number: 20180125799
    Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 10, 2018
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Mohammad AZAM, Meenu KESARWANI
  • Therapy for leukemia
    Patent number: 9877934
    Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 30, 2018
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Mohammad Azam, Meenu Kesarwani
  • THERAPY FOR SOLID TUMORS
    Publication number: 20170079979
    Abstract: A pharmaceutically acceptable composition and method for solid tumor therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, and (b) an inhibitor of Dusp-1, and optionally (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for solid tumors.
    Type: Application
    Filed: May 29, 2015
    Publication date: March 23, 2017
    Inventors: Mohammad Azam, Meenu Kesarwani
  • THERAPY FOR LEUKEMIA
    Publication number: 20140031356
    Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.
    Type: Application
    Filed: October 8, 2013
    Publication date: January 30, 2014
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Mohammad AZAM, Meenu Kesarwani